Cuproptosis-related gene SLC31A1: prognosis values and potential biological functions in cancer

Cuproptosis is a unique type of cell death that may influence tumour formation by targeting lipoylated tricarboxylic acid cycle proteins. Solute carrier family 31 member 1 (SLC31A1), an important copper transporter, influences dietary copper absorption in the cell membrane. However, various SLC31A1 properties in pan-cancer profiles remain unknown. This study investigated the role of SLC31A1 in human malignancies and analysed its prognostic value. Raw data were obtained from The Cancer Genome Atlas database and processed using numerous internet databases, including UALCAN, GEPIA, cBioPortal, TIMER2.0, and Human Protein Atlas. SLC31A1 expression was found to be elevated in cervical, endometrial, and breast cancers compared to that in normal tissues, but reduced in clear cell renal cell carcinoma, liver hepatocellular carcinoma, and lung adenocarcinoma. Furthermore, SLC31A1 expression was strongly associated with overall survival and disease-free survival in several cancers. SLC31A1 gene mutations and methylations were identified in 33 cancers. SLC31A1 expression was positively correlated with immune cells in immune infiltration data. Single- cell sequencing revealed that SLC31A1 may play key roles in DNA repair, DNA damage, and proliferation. These findings may lead to better understanding of SLC31A1 in pan-cancer profiles and suggest that SLC31A1 could be a viable predictive biomarker, particularly in gynaecological cancers.

Automated summary

This study investigates the role of SLC31A1, an important copper transporter, in human malignancies and its association with cancer prognosis. The findings show that SLC31A1 expression is elevated in cervical, endometrial, and breast cancers, but reduced in clear cell renal cell carcinoma, liver hepatocellular carcinoma, and lung adenocarcinoma. SLC31A1 expression is strongly correlated with overall survival and disease-free survival in several cancers. Furthermore, SLC31A1 gene mutations and methylations were identified in 33 cancers. These results provide valuable insights into the role of SLC31A1 in pan-cancer profiles and suggest its potential as a predictive biomarker, particularly in gynaecological cancers.